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Abstract
Background: The individual and societal burden of hand eczema is high. Literature indicates that moderate to severe hand
eczema is a disease with a poor prognosis. Many patients are hampered in their daily activities, including work. High costs are
related to high medical consumption, productivity loss and sick leave. Usual care is suboptimal, due to a lack of optimal
instruction and coordination of care, and communication with the general practitioner/occupational physician and people
involved at the workplace. Therefore, an integrated, multidisciplinary intervention involving a dermatologist, a care manager, a
specialized nurse and a clinical occupational physician was developed. This paper describes the design of a study to investigate
the effectiveness and cost-effectiveness of integrated care for hand eczema by a multidisciplinary team, coordinated by a care
manager, consisting of instruction on avoiding relevant contact factors, both in the occupational and in the private environment,
optimal skin care and treatment, compared to usual, dermatologist-led care.
Methods: The study is a multicentre, randomized, controlled trial with an economic evaluation alongside. The study population
consists of patients with chronic, moderate to severe hand eczema, who visit an outpatient clinic of one of the participating 5
(three university and two general) hospitals. Integrated, multidisciplinary care, coordinated by a care manager, including allergo-
dermatological evaluation by a dermatologist, occupational intervention by a clinical occupational physician, and counselling by
a specialized nurse on optimizing topical treatment and skin care will be compared with usual care by a dermatologist. The
primary outcome measure is the cumulative difference in reduction of the clinical severity score HECSI between the groups.
Secondary outcome measures are the patient's global assessment, specific quality of life with regard to the hands, generic quality
of life, sick leave and patient satisfaction. An economic evaluation will be conducted alongside the RCT. Direct and indirect costs
will be measured. Outcome measures will be assessed at baseline and after 4, 12, 26 and 52 weeks. All statistical analyses will
be performed on the intention-to-treat principle. In addition, per protocol analyses will be carried out.
Discussion: To improve societal participation of patients with moderate to severe hand eczema, an integrated care intervention
was developed involving both person-related and environmental factors. Such integrated care is expected to improve the
patients' clinical signs, quality of life and to reduce sick leave and medical costs. Results will become available in 2011.
Published: 1 December 2009
BMC Public Health 2009, 9:438 doi:10.1186/1471-2458-9-438
Received: 6 August 2009
Accepted: 1 December 2009
This article is available from: http://www.biomedcentral.com/1471-2458/9/438
© 2009 van Gils et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 8
(page number not for citation purposes)
BMC Public Health 2009, 9:438 http://www.biomedcentral.com/1471-2458/9/438Background
The individual and societal burden of hand eczema is
high. Hand eczema is a prevalent disease according to
long-term registrations in general practitioner's-practices.
Prevalence ranges from 25 to 66 cases per 1000 patient
years. Point prevalence varies from 5 to 10% and inci-
dence rates from 4 to 7% [1,2]. Self-reported life-time
prevalence comes to more than 30% of the respondents.
Hand eczema accounts for 90% of the occupational skin
diseases and is in the top three of registered work-related
disorders [3]. Literature also indicates that hand eczema is
a disease with an unfavourable prognosis. The patho-
mechanism of hand eczema is often multifactorial. Both
endogenous and exogenous factors play a role in its
pathomechanism. Even meticulous avoidance of contact
factors does not grant cure. Less than 50% of the patients
has been reported to be cured after 5 years [4].
Significant numbers of patients suffer from this disease
and are hampered in their daily activities and work. The
physical and psychosocial burden for patients with skin
diseases is comparable to patients with other chronic dis-
eases, like multiple sclerosis and migraine, and even
higher than patients with diabetes mellitus. In 18% of the
patients symptoms of a clinical depression is present [5].
Medical consumption is also high; 60% visit their general
practitioner in a year and 20% visit a medical specialist.
High costs are also related to productivity loss and sick
leave. In the Netherlands, annual costs of medical care,
absenteeism and disability pensions due to occupational
skin disease in employees in 2001 were estimated at €
98,1 million [6].
Although the individual and economic burden is high, the
current usual care by dermatologists is thought to be sub-
optimal. Coordination of care is essential to ensure opti-
mal avoidance of relevant contact factors at home and in
the working environment. Usual care does not include
consultation with the general practitioner or occupational
physician, and the people involved in the workplace.
Hence, suboptimal care for patients with occupational
skin disease may lead to long-term absenteeism and ulti-
mately to permanent disability with unnecessarily high
costs [7]. Patients are in need of extensive counselling to
improve their situation, as hand eczema has a complex
aetiology and runs a dynamic but chronic course. Patients
need instruction and information on topical therapy,
aggravating factors and preventive measures. Usual care
cannot provide for this, because of the limited time and
expertise available at most outpatient clinics [8,9].
Recent data indicate a better prognosis due to secondary
prevention and protocolled intervention. A recent system-
atic review indicated that usual care for eczema can be
improved by active care management by a nurse practi-
tioner, with doctors often lacking the time to offer suffi-
cient patient education, and to manage complexly
organized care of chronic illnesses effectively[10]. This
perspective prompted us to start with integrated, multidis-
ciplinary care for hand eczema patients, aiming at optimal
topical treatment, avoiding relevant contact factors at
home and in the working environment as much as possi-
ble, and optimal compliance to proper skin care instruc-
tion. Based on available data and this systematic review,
we hypothesize that integrated, coordinated multidiscipli-
nary care will lead to improved clinical signs of hand
eczema and quality of life, and a reduction in absenteeism
from work.
Objective
In this paper, we describe the design of a randomized con-
trolled trial (RCT) comparing integrated care for hand
eczema by a multidisciplinary team, with usual care by a
dermatologist. The multidisciplinary team involves a der-
matologist, a specialized nurse and a clinical occupational
physician. The specialized nurse also serves the role of
care manager, and is responsible for the coordination of
the integrated care. The primary research question is 'Is
integrated care for hand eczema by a multidisciplinary
team effective and cost-effective, compared to usual care?'
Methods
Design of the study
The design of the study is a randomized controlled trial
with a full economic evaluation alongside, with a follow-
up of one year. The design is presented in figure 1. The
Medical Ethics Committees of the participating hospitals
(the VU University Medical Centre, Radboud University
Medical Centre, Groningen University Medical Centre,
Canisius Wilhelmina Medical Centre and Jeroen Bosch
Medical Centre) approved the study. All participants will
sign an informed consent. Exemption from insurance was
granted by the Medical Ethics Committee of the VU Uni-
versity Medical Centre.
Participants
The population consists of patients (16 years and older)
with chronic (> 3 months) hand eczema who visit a der-
matologist of one of the participating hospitals. The
degree of hand eczema is determined using the Photo-
graphic Guide [11]. Patients with moderate to severe hand
eczema are eligible. Patients with mild hand eczema who
are on sick leave from work, or who score at least 4 points
on a Visual Analogue Scale (VAS) for perceived burden of
disease in the last three months before inclusion are eligi-
ble also. Exclusion of patients occurs in case of 1) general-
ized eczema, where hand eczema is not the main disease;
2) use of topical pharmacotherapy or phototherapy, other
than used in the study; 3) systemic treatment affecting
hand eczema; 4) inability to complete questionnairesPage 2 of 8
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will be given the patient information letter by their der-
matologist and will be contacted by the researchers by tel-
ephone. In this contact, the researcher provides additional
information about the consequences of participation. If
the patient continues to be willing to participate, the
researchers plan a face-to-face appointment to sign the
informed consent form, to obtain baseline measurements
and to perform the randomization procedure. Patients
will be asked to fill out a form to allow their general prac-
titioner or occupational physician, to provide informa-
tion regarding medication and other relevant medical
information to the multidisciplinary team.
Randomization
Patients will be randomized by the research assistant
using sealed opaque envelopes. Randomization will be
performed at individual patient level. Stratification will be
applied for: 1. Medical centre, 2. Risk profession and/or
activities, according to the guideline Contact Eczema [12].
Random length blocks will be generated for each stratum
by means of a computer-generated random sequence
table. An independent statistician will prepare sequen-
tially numbered sealed envelopes containing leaves that
indicate the intervention group or the control group.
Treatment allocation will take place after informed con-
sent and completion of baseline measurements. After ran-
domization, the outcome of the randomization will be
reported by the research assistant to the patient and the
dermatologist.
Blinding
Clinical scoring of the primary outcome measure will be
performed by an independent trained clinical investiga-
tor, who will be blinded for allocated treatment. The ther-
apists of the multidisciplinary team will not be involved
in assessing any of the outcomes. Participants and health
professionals cannot be blinded for the allocated treat-
ment. Because the questionnaires will be sent to the
patient by mail, researchers and care providers are not
likely to influence the way patients complete the ques-
tionnaires. After randomization, all participants will
receive a non traceable research code consisting of a con-
secutive number. A research assistant will enter all data in
the computer by the research code. Therefore, the analyses
of the data by the researchers will be blind.
Interventions
Integrated care by the multidisciplinary team
The group of patients randomized to the integrated care
for hand eczema in a specialized centre will receive coor-
dinated care by a multidisciplinary team. The multidisci-
plinary team consists of a care manager (an in
dermatology specialized physician assistant or nurse), a
dermatologist, an occupational physician and a special-
ized nurse. All professionals will be trained in the study
protocol prior to the study, with a refresher course after a
half year. The specific role of each member is described
below.
1. The care manager: coordination and communication
The care manager coordinates the integrated care. He/she
is responsible for communication of the treatment plan
with the patient. In addition, the care manager is respon-
sible for the communication with all stakeholders, in the
hospital (dermato-allergologist, occupational physician)
as well as the relevant stakeholders in primary care (the
patient's general practitioner and if applicable occupa-
tional physician and occupational hygienist). The care
manager will have an intermediary role between primary
and secondary care.
2. Multidisciplinary team: discussion
All patients will be discussed weekly in the multidiscipli-
nary team. The outcomes of this discussion will be the
guideline for further treatment.
3. Dermatologist: clinical evaluation
The dermatologist will perform the clinical and allergo-
dermatological evaluation. This includes thorough his-
tory taking (including relevant exposures), physical exam-
ination and allergological testing. In addition to the
Design of the RCTFigure 1
Design of the RCT.
Usual care by the 
dermatologist 
(N=100) 
Follow-up 
measurements at 4, 12, 
26 and 52 weeks after 
inclusion 
Checking eligibility criteria 
Recruiting patients 
Informed consent 
Baseline measurement 
Randomization 
Transmural care by the 
multidisciplinary team  
(N=100) 
Follow-up 
measurements at 4, 12, 
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small series of aero-allergens and/or epicutaneous tests
with the European baseline series [13]), and a routine
additional series) as in usual care, series relevant for the
situation of the patient at work and at home can be tested
with dilution series and controls.
4. Specialized nurse: topical treatment and education
All patients will visit the specialized nurse after 1, 4, 8 and
12 weeks. Another visit after 2 weeks is optional (figure 2).
An essential part of the visits is education and counselling
of the patient in the compliance to topical treatment. Top-
ical treatment will be standardized. The approach is step-
wise and strictly protocol led. Depending on the status of
the hand eczema (acute, sub-acute or chronic lesions) and
the overall severity (investigator's global assessment, [11])
a topical treatment regimen will be selected and adjusted
during follow-up visits if needed. Treatment consists of
dermatocorticosteroids and emollients, if needed supple-
mented with calcineurin-inhibitors.
Another important part of the programme is education of
the patient, in order to improve his understanding of the
mechanics of eczema and the circumstances that influ-
ence the barrier function of the skin. Instruction and
counselling will be given regarding work, hand washing
and care procedures, the use of protection measures such
as protective gloves in general and the use of cotton gloves
worn underneath. If necessary, information will be pro-
vided by the specialized nurse also for colleagues.
5. Clinical occupational physician: information, instruction and 
workplace visit
The clinical occupational physician will be involved if
hand eczema is work-related (occupational dermatitis or
work-aggravated dermatitis), or when (potential) absen-
teeism as a result of hand eczema threatens (figure 2).
Information will be gained about exposure to skin irritat-
ing circumstances and the use of protective measures. In
addition to the standard allergo-dermatological testing
(European baseline series and additional (occupational)
series), material derived from the workplace can be tested.
Workplace visits will be organised, if indicated, to gain rel-
evant material for testing or information on work circum-
stances. The clinical occupational physician will also give
advice about prevention and work procedures. If needed,
Flowchart of the interventionigure 2
Flowchart of the intervention. 1: in case of work-related/occupational dermatitis or aggravated dermatitis, and/or in case 
of (potential) absenteeism. 2: in case of Incomplete task analysis, Unknown substances, Causal relation unknown earlier, 
(Potential) absenteeism or if Contact with supervisor is indicated. *: in case of (potential) absenteeism, incomplete task analysis, 
advices about modified/alternative work or supplementary material needed. **: in case of insufficient diagnostic information/
supplementary material needed, insufficient information for proper treatment or care/prevention advice. ...: information flow. 
__: referral; ---: referral if indicated.
Week 0: Multidisciplinary team discussion (MTD):  
Dermatologist, Specialized Nurse (SN) and Clinical Occupational Physician (COP) 
Week 1: Visit SN
Week 2: Visit SN (optional)
Week 4: Visit SN + dermatologist
Week 8: Visit SN
Week 12: Final visit SN + 
dermatologist
Visit COP, if indicated 
Contact with supervisor/ occupational 
physician if indicated *  
Workplace visit if indicated ** 
Feedback through weekly discussion
Weekly follow up MTD 
2
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nication with the employer's supervisor. Contact with the
employer's supervisor or occupational physician will take
place if indicated.
Web-based patient tracking system
The process of the intervention will be recorded using a
web-based patient tracking system. All professionals will
receive a unique username and password. For each
patient, data about each particular visit will be registered.
Professionals will be alerted if an appointment has to be
made. The care manager will be responsible for the input
of data by all professionals. The web-based patient track-
ing system supports the professionals to deliver care
according to the protocol.
Usual care
The patients who are allocated to the usual care group will
receive allergological evaluation (intra-cutaneous tests
and/or epicutaneous test with the European baseline
series and additional series) delivered by the patient's own
dermatologist, not working in a specialized centre. The
patient's own dermatologist will also be responsible for
further usual medical care, such as pharmacotherapy, pro-
vision of standard written information and advices. The
patients' own general practitioner, occupational physician
and treating medical specialist will be informed by letter
about the study and the allocation of their patient to the
usual care group. They will be asked to adhere to their nor-
mal treatment for hand eczema.
Data collection
Clinical scores of hand eczema and self-reported ques-
tionnaires will be assessed by an independent and
blinded clinical investigator at baseline and after 4, 12, 26
and 52 weeks. The clinical investigators will be trained in
scoring methods prior to the study, with multiple
refresher courses throughout the study. Self-reported
questionnaires will be handed out and filled in at the
same moments. Prognostic outcomes will be assessed at
baseline. The direct and indirect medical costs will be
measured monthly by means of cost calendars. Additional
questions about the multidisciplinary care will be
attached to the 12-week questionnaire of the first 30
patients randomized to the intervention group. A ques-
tionnaire about the patients' satisfaction with health care
will be attached to the 12-week questionnaire of all
patients.
Outcome measures
Primary outcome
The primary outcome measure of the study is the cumula-
tive difference in reduction of the clinical severity score
HECSI (Hand Eczema Severity Index, [14]). The cumula-
tive difference is defined as the area under the curve of the
scores at baseline and after 4, 12, 26 and 52 weeks. The
HECSI measures clinical severity of hand eczema on the
following signs: 1. Erythema, 2. Infiltration/Papulation, 3.
Vesicles, 4. Fissures, 5. Scaling and 6. Oedema. It will
focus on the fingertips, the palm of the hand, the back of
the hand and the wrists. For each area the intensity of each
sign will be graded on the following scale: 0, no skin
changes; 1, mild disease; 2, moderate and 3, severe. For
each location, the affected area will be given a score from
0-4 (0 = 0%, 1 = 1-25%, 2 = 26-50%, 3 = 51-75% and 4 =
76-100%) for the extent of clinical symptoms. Finally, the
score given for the extent for each location will be multi-
plied by the total sum of the intensity of each clinical sign.
The total sum is called the HECSI score, varying from 0 to
a maximum of 360 points.
Secondary outcomes
- Other clinical severity measures. Various symptoms
will be scored using the Hand Eczema Area and Sever-
ity index (HEAS, [15]). This score is comparable to the
HECSI in symptoms measured, but scores both hands
separately.
- Disease-specific quality of life. The impact of hand
eczema on the patient's quality of life is measured
using a modified Dutch version of the Impact of
chronic Skin Disease on daily Life (ISDL, [16]), in
which the term 'skin disease' is replaced with 'hand
eczema', and the Skindex [17]. The questionnaires dis-
cuss multiple aspects of hand eczema, such as impact
on daily routine and work, and emotional and societal
burden.
- Generic quality of life, using the standard Dutch ver-
sion of the EuroQoL EQ-5D [18].
- Patients' global assessment, using a self-constructed
Visual Analogue Scale (VAS).
- Total number of days of sick leave, using a monthly
calendar.
- Direct medical costs are measured using cost calen-
dars. The cost calendar includes direct costs relevant to
the treatment of hand eczema, such as visits to the gen-
eral practitioner, occupational physician or occupa-
tional hygienist and purchase of medication.
- Patient satisfaction will be measured with the Patient
Satisfaction with Occupational Health services Ques-
tionnaire (PSOHQ, [19])
- Health care professionals' compliance to transmural
care, advises and protection measures will be evalu-
ated in a process evaluation.Page 5 of 8
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Hand eczema is strongly related to wet and dirty activities
or work. Working in a high risk job or with specific mate-
rials is considered to be prognostic for hand eczema. To
determine risk profession, the guideline for contact
eczema of the Dutch association for occupational health
will be used [12].
Sample size
The sample size calculation is based on a pilot study car-
ried out in the Radboud University Medical Centre. In this
pilot study, the Hand Eczema Area and Severity score
(HEAS) was used. In the pilot study, a reduction in HEAS
of 50% was observed during the first six months after the
intervention. A reduction of this percentage to 40% dur-
ing the next six months is hypothesized. The standard
deviation (on a logarithmic scale) of the HEAS was 1.2
and the correlation between measurements from 1 to 6
months apart was 0.5. The correlation did not depend on
the length of the interval. Based on these findings, a two-
sided type 1 error of 5% and a power of 80%, 85 evaluable
patients with at least three follow-up assessments are
required per treatment group. Taking into account 30
dropouts, 200 patients will be enrolled, equally distrib-
uted over the centres.
Co-interventions and compliance
During the intervention period co-interventions cannot
always be avoided. In the intervention group, the patient's
general practitioner will receive a letter, in which he/she is
asked to leave the treatment of hand eczema to the multi-
disciplinary staff. Information about all treatments and
co-interventions received by the patients will be collected
by means of cost-calendars and questionnaires.
Data analysis
All analyses will be performed at patient level. To examine
the success of randomization, descriptive statistics will be
used to compare the baseline measurements of the two
groups. The primary analysis will be based on the inten-
tion-to-treat principle. For each patient, the area under the
curve (AUC) of the HECSI scores over the period from 4
weeks to one year will be determined. An analysis of cov-
ariance will then be carried out with the logarithm of the
AUC as dependent variable and treatment group, the log-
arithm of the baseline HEAS and the stratification factors
of the randomisation as independent variables. In addi-
tion, per protocol analyses will be performed. In an
exploratory analysis, other baseline covariates will be
added to the model. Other endpoints will be analysed in
the same way.
Economic evaluation
Cost-effectiveness will be evaluated form a societal per-
spective. Monthly costs calendars will be used to measure
direct and indirect medical costs and sick leave. The cost
calendars will include direct health care costs relevant to
the treatment of hand eczema, such as visits to a general
practitioner or an occupational practitioner and self-
bought medication or skin protection tools. Sick leave as
a result of hand eczema will be registered monthly using
the same calendar. Medical costs related to the study pro-
tocol will be obtained from the web-based tracking sys-
tem, which keeps track of all visits to health care
professionals and medication prescribed. Health care
costs will be valued according to the prices suggested in
the guidelines for economic evaluation in the Netherlands
[20,21]. If cost-guidelines are not available, costs will be
estimated using real prices. Costs of lost productivity
caused by (partial) sick leave due to hand eczema will be
calculated from the number of days of sick leave. Indirect
costs will be calculated using the friction cost approach
and the human capital approach. Quality-Adjusted Life
Years (QALYs) will be computed in order to perform a
cost-utility analysis for the two alternative treatments.
Utilities will be based on the mean values for the two
groups of patients at baseline and follow-up measure-
ments. Costs will be summated for each individual
patient. Bootstrapping will be used for pairwise compari-
son of the mean groups to calculate mean differences in
direct, indirect and total costs between the two groups of
patients. An incremental cost-effectiveness ratio (ICER)
will be calculated by dividing the difference between the
mean costs of the two groups by the difference in relative
reduction (percentage point) between the two groups. A
cost-utility analysis will also be conducted in which the
incremental costs per QALY will be estimated. Reliability
of the cost-effectiveness ratios will be graphically pre-
sented on a cost-effectiveness plane and in acceptability
curves. To compare the results of the cost-effectiveness
analysis with other conditions, general health status will
be measured according to the Dutch version of the Euro-
Qol EQ-5D [18].
Discussion
This study protocol presents a randomized controlled trial
to investigate the (cost-) effectiveness of integrated, multi-
disciplinary care for hand eczema. Usual care mainly
focuses on improving clinical signs of hand eczema and
does not have major focus on the patient's participation in
society. Attention to societal participation is necessary to
reduce the high costs related to productivity loss and high
risk for long-term disability and accompanied physical
and psychological burden for the patient. Therefore, an
integrated care program has been developed.
Theoretical basis
An integrated care program was developed based on the
International Classification of Functioning, disability and
health (ICF, [22]). In line with the ICF, this integrated carePage 6 of 8
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it also focuses on increasing social participation. The ulti-
mate goal of the intervention is to optimize the patient's
quality of life and social functioning.
Integrated care is a system intervention where multiple
systems are incorporated. First, the health system, where
health care professionals cooperate to improve not only
clinical signs, but also strive towards an increase in partic-
ipation. This enables consensus about the treatment and
the advice given. Next, the private and work systems are
incorporated in the integrated care program. By focusing
on personal factors to increase self-management, and by
investigating the workplace, every actor in the environ-
ment is actively involved to reach a similar goal: improve-
ment of participation. In order to achieve a systematic
change in all systems, personal as well as environmental
factors are addressed in the treatment.
Based on the biopsychosocial model [23], integrated care
aims to achieve behavioural change in the patient, by
means of counselling using a cognitive-behavioural
approach. Thereby, the patients' coping with hand eczema
improves and his self-management increases.
Besides that, integrated care aims to minimize the
patients' exposure to causal factors, for example by using
the appropriate protection measures. The home situation
as well as the workplace are taken into account. If the
patient cannot fulfil his daily work, the possibility of
modified or alternative work will be discussed. If needed,
the patient's relatives or colleagues and supervisors are
included in the treatment.
Impact of results
Besides an improvement of clinical outcomes, we expect
an increase of the patient's quality of life. If the interven-
tion shows to be effective, it could be implemented on a
larger scale. By increasing the patient's self-management
of hand eczema, we also expect a decrease of medical con-
sumption and fewer episodes of sick leave in the long
term.
Results will become available in 2011.
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